One product, one panel, one record.
Jarrow Formulas Saccharomyces Boulardii + MOS, 5 Billion CFU, 90 Delayed-Release Veggie Caps — label audit
The label says "clinically shown" and "clinically studied probiotic" about an organism it never identifies to strain — while the same brand, on the same website, designates all eight strains on its neighbouring product. The omission is a choice, not a house policy.
This page is an audit of a label. It records what this product’s panel discloses, what of that could be checked against a primary record, and what could not. The score below ranks this product on that disclosure and on nothing else.
The record this page rests on
- NIH label record
- Label read on
- The most recent dated artefact behind this page. Labels change; this is how old our reading of it is.
- Cohort
- Addendum — outside the founding denominators Audited 2026-07-31, outside the frozen founding cohort of 27 and outside every D27 denominator.
- How deep this went
- Label audit — the lighter pass What the label says, what basis it gives for its CFU number, whether the strains are coded, whether a government label record exists — checked and published. No full claim inventory was written for this SKU. It is a real result, and it is a shallower one than the teardowns above it, which is why the page says so before you weigh it against them.
The Label Verifiability Score for this product
48.8 out of 100
Rank 96 of the 154 products in this audit the rubric can score. This rank is shared with 1 other product — 2 products sit on 48.8 and are tied. They hold the position jointly; no tiebreaker is applied, because every tiebreaker available here would be a number the rubric deliberately refused to weigh, smuggled back in to make a list look tidier.
The score measures one thing: how much of what you are buying this company tells you, and how much of that survives being checked against a source that is not the company. It does not measure whether the product works — this site holds no efficacy data of its own, and 0 of 294 organism slots in the founding cohort carry a strain with a human randomised trial for any male-specific outcome, so nobody in this category has evidence that would support a ranking by effect.
Computed over 86% of the rubric by weight — the share of the five questions below this record could answer. The remaining question is unanswered, and unanswered is not nought: it leaves the divisor rather than dragging the score down. That share travels with the number and is never dropped — this score over 86% of the weight and the same score over all of it are different claims.
| Component | Weight | What was counted, and where | Fraction | Weight × fraction |
|---|---|---|---|---|
| Strain identity printed on the panel | 0.24 | 0 of 1 organism slot carries a printed strain designator. | 0 / 1 = 0.0000 | 0.0000 |
| Per-organism amount printed | 0.20 | 1 of 1 organism slot has an amount of its own; the rest are inside a blend total. | 1 / 1 = 1.0000 | 0.2000 |
| What the CFU count is measured against | 0.22 | Potency basis "through-expiry": CFU figure printed yes, single basis stated yes, basis reaches expiry yes — 3 of 3. | 3 / 3 = 1.0000 | 0.2200 |
| Printed designators that lead to a human trial | 0.20 | 0 of 1 checked organism slot resolves to at least one human randomised trial under the designator exactly as printed. This counts whether the identity leads to a trial, never what the trial found. | 0 / 1 = 0.0000 | 0.0000 |
| Certification confirmed at the issuer’s own register | 0.14 | Every certification on this record is brand-asserted with the register unreachable, or not yet queried. An unreachable register is a fact about the verification infrastructure, not about this brand, so it may not move its position. | Not answered | — excluded from the divisor, not counted as nought |
0.4200 — the last column added up — divided by 0.86, the weight this record could answer, is 0.4884. Multiplied by 100 and rounded to one decimal, that is the 48.8 above.
See this product’s row in the full ranking, alongside the other 153 scored products, or read what each of the five components asks and how to check it .
What this label discloses
Everything in this table is what the product itself states — on the printed panel, on the brand’s own page, or in the label record the manufacturer filed. Nothing in it is checked yet; checking is the next section.
| Disclosure | As recorded |
|---|---|
| CFU as printed | Saccharomyces boulardii (an S. cerevisiae strain) — 250 mg (5 Billion CFU) |
| What that count is measured against | Through expiry |
| Strain designators | None — species only |
| Organism slots transcribed here | 1 — the full panel |
| Marketed as | Unisex |
"Minimum 5 billion viable cells at time of consumption, under recommended storage conditions and within Best Used Before date." At-expiry, and "at time of consumption" is unusually consumer-framed phrasing — the strongest form of the claim in this batch. No refrigeration required.
The panel’s own words on potency, verbatim.
The panel guarantees the count through the expiration or best-by date. This is the only basis that is falsifiable by a reader holding the bottle.
The panel names species only, with no strain designator anywhere. A species name is not a claim: the trials in this field are of strains, and a species can contain thousands.
| Organism as printed | Designator as printed | Quantity as printed | What the designator resolves to | The query we ran |
|---|---|---|---|---|
| Saccharomyces boulardii (an S. cerevisiae strain) | — none printed | 250 mg (5 Billion CFU) | No designator printed | — |
What of that is verifiable
A disclosure is verifiable when a reader can open a record that neither we nor the brand controls and see the same thing. Below is every dated artefact this page rests on. What is absent from this list is not verified, however reasonable it sounds.
- NIH Dietary Supplement Label Database record — DSLD 307727 (opens in a new tab) captured On-market. UPC cross-check passed — DSLD upcSku 7 90011 03004 1 matches jarrow.com's JSON-LD gtin12 790011030041 on the "90ct" offer, sku SAC. Ingredient rows are "Saccharomyces boulardii | 250 mg" and "MOS Yeast Fraction | 200 mg", with no nested strain identifier — an independent confirmation that no designator exists on this label. Free-from statement: vegan, gluten free, "No wheat, gluten, soybeans, dairy, egg, fish/shellfish, peanuts/tree nuts or sesame."
- Dated capture of the brand’s own page — jarrow-sac-90-2026-07-31https://jarrow.com/products/saccharomyces-boulardii-mos-5-billion-cfu-delayed-release-veggie-caps — Address given, not linked: this site does not link out to the products it audits. captured HTTP 200. Source for price ($30.99 for 90 ct, $50.99 for 180 ct), for the at-expiry wording quoted above, for the "clinically shown" copy, and for the prebiotic spec — "MOS Yeast Fraction (Min. 35% Manno-oligosaccharides [MOS]) (S. cerevisiae) — 200 mg", a minimum-purity specification rather than a bare milligram figure. Also carries an honest pre-emption of a common complaint, verbatim: "Note: Capsule fill content may change, due to raw material particle size. However, potency remains the same."
How many of its strains have a human trial for what it is sold for
Across the frozen founding cohort, 0 of 294 organism slots (0.0%) carry an organism with a human randomised controlled trial for any male-specific outcome. Not for this product — for all 27 of the founding teardowns, taken together. That is the number to hold against any men’s probiotic, including this one.
Two further founding-cohort figures for context: only 43 of 294 organism slots carry a strain with any human RCT at all under the exact code printed on the label, and only 2 of 27 products have a published human trial of the finished formula — the thing actually in the bottle. All three figures divide by the frozen cohort of 27 teardowns and 294 organism slots, never by every teardown on this site.
For this product specifically, 0 organism slots carry a strain with a human RCT under the exact designator printed on the label.
A word on what a designator has to clear before it counts here. The organism must be named with the exact strain code that appears in the trial, the trial must be in humans, and the code must return that trial when a reader searches it. A species name does not qualify: the trials in this field are of strains, and a species contains thousands of them.
What it costs per day
$0.34 a day at the dose the label itself instructs.
- Price
- $30.99 USD
- What that buys
- 90 capsules, 1 capsule once daily, 90 servings per container. A 180-count pack (sku SAC180) lists at $50.99.
- Price checked
- — the source we read it fromhttps://jarrow.com/products/saccharomyces-boulardii-mos-5-billion-cfu-delayed-release-veggie-caps — Address given, not linked: this site does not link out to the products it audits.
What certification it holds, checked at the issuer’s own register
A badge on a bottle is a claim like any other. Every row below was checked — or not checked — at the certifier’s own public register, never at the badge. Across the frozen founding cohort, 2 of 27 products hold a certification we could confirm at the issuer — a founding-cohort figure, not a count over every teardown on this site.
| Programme | Status at the issuer | Checked |
|---|---|---|
| IPRO (International Probiotic Testing Standards, SGS Nutrasource) | Register unreachable | 31 July 2026 |
| IGEN Non-GMO Tested | Register unreachable | 31 July 2026 |
IPRO (International Probiotic Testing Standards, SGS Nutrasource)
The certifier’s register could not be queried at all. That is a finding about the verification infrastructure, not about the brand.
Line-level certification is confirmed at the issuer: nutrasource.ca, 22 June 2020, "the Jarrow Probiotic line is now certified through the International Probiotic Testing Standards (IPRO)". Per-SKU currency could not be confirmed because nutrasource.ca/certified-products returned HTTP 500 and igenprogram.com/certified-products returned 404. Recorded as issuer-confirmed at line level in 2020, per-SKU currency unverified — not "verified" and not "does not hold it".
IGEN Non-GMO Tested
The certifier’s register could not be queried at all. That is a finding about the verification infrastructure, not about the brand.
Same issuer, same register outage. Brand-asserted, unverified.
How it differs from the same brand’s women’s version
Across the fourteen same-brand men’s-versus-women’s label diffs run inside the frozen founding cohort, zero men’s or default formulas contain a probiotic strain, identified by designator, that was selected on male-specific evidence. In eight of the fourteen the sex-specific differentiator is a botanical or a mineral, and in five of the fourteen the women’s SKU is better-specified, cheaper, or both — “better-specified” meaning the panel that discloses more, never the panel with more in it. The rule behind each of those counts, and all fourteen pairs classified against it , are published in full. Diffs run on teardowns added since sit outside this fourteen, and outside the sentence above.
Every finding on this page, with the record behind it
Finding 1 no-strain-designator-on-a-product-whose-clinical-story-depends-on-one
S. boulardii is a strain grouping within S. cerevisiae, and the human clinical literature runs almost entirely on CNCM I-745. A label that says "S. boulardii" without a designator is naming the genus-species of a clinical literature it has not established it participates in.
The record: jarrow.com panel and DSLD 307727 ingredient rows, both 2026-07-31 — open it (opens in a new tab)
Finding 2 clinically-shown-attached-to-an-unidentified-strain
Label copy, verbatim: "Saccharomyces Boulardii is a probiotic yeast clinically shown to benefit individuals in greater need for intestinal support, such as those who travel", and "Clinically studied probiotic." The trials being alluded to were run on CNCM I-745, which this label does not claim to contain. This is the strain-swap substantiation gap in its purest form.
The record: jarrow.com product page copy, verbatim, 2026-07-31
Finding 3 the-same-brand-designates-every-neighbouring-sku
Jarro-Dophilus EPS, on the same website, names all eight of its strains. This product names none — and it is the one product in the line where the designator carries the entire clinical argument. That makes the omission a choice rather than a house policy.
The record: jarrow.com Jarro-Dophilus EPS 10B and 25B panels versus this panel, all 2026-07-31
Finding 4 filed-under-womens-health-without-a-stated-rationale
The brand's own on-page category list files this product under "Women's Health". S. boulardii has no sex-specific rationale and none is given.
The record: jarrow.com product page category list, 2026-07-31
What we could not verify
Every gap below is published rather than deleted. Most are derived automatically from the empty fields in this page’s own record, so a gap cannot be hidden by leaving a box blank.
- IPRO (International Probiotic Testing Standards, SGS Nutrasource) status
- Line-level certification is confirmed at the issuer: nutrasource.ca, 22 June 2020, "the Jarrow Probiotic line is now certified through the International Probiotic Testing Standards (IPRO)". Per-SKU currency could not be confirmed because nutrasource.ca/certified-products returned HTTP 500 and igenprogram.com/certified-products returned 404. Recorded as issuer-confirmed at line level in 2020, per-SKU currency unverified — not "verified" and not "does not hold it".
- IGEN Non-GMO Tested status
- Same issuer, same register outage. Brand-asserted, unverified.
- A men’s-versus-women’s label diff
- The same brand’s women’s SKU has not been compared against this panel.
- Which Saccharomyces boulardii strain is in this product
- No designator is printed on the label and none is recorded in the federal label database. Two independent sources agree that the identifier is absent, so the question is unanswerable from anything published.
- Whether any of the S. boulardii clinical literature applies to this product
- It cannot be established either way. The trials being alluded to were run on CNCM I-745. This label does not claim to contain CNCM I-745, and it does not claim to contain anything else specific either.
- Per-SKU currency of the IPRO and IGEN marks
- The issuer's per-SKU registers returned HTTP 500 and 404. See the certification detail.
How to check every line of this page yourself
Nothing on this page requires trusting us. Every claim above resolves to a record you can open:
- Open the NIH Dietary Supplement Label Database record linked at the top of this page. It is the label the manufacturer filed, not our transcription of it.
- Compare the CFU line and the suggested-use line against the disclosure table above. If they disagree with us, we are wrong and we want to know.
- Take any strain designator from the panel and run the query printed beside it. The query is published precisely so you can get a different answer than we did.
- Divide the price by the number of days the label’s own dose instructions make the container last. That arithmetic is the whole of the cost-per-day row.
- Search the certifier’s own register for this product, not for the brand. A company can participate in a programme without this product being on its list.
Saccharomyces boulardii is not really a species. It is a strain grouping inside S. cerevisiae, and essentially the entire human clinical literature attached to the name runs on one designated strain: CNCM I-745, the strain sold as Florastor. Search the exact phrase and 148 publications come back, ten of them randomised trials.
This label does not claim to contain CNCM I-745. It does not claim to contain any particular strain at all — the panel reads “Saccharomyces boulardii (an S. cerevisiae strain) — 250 mg (5 Billion CFU)” and stops, and the federal label record independently confirms there is no nested identifier. Two sources agree that the designator is absent.
Then the copy makes the leap anyway: “Saccharomyces Boulardii is a probiotic yeast clinically shown to benefit individuals in greater need for intestinal support”, and, elsewhere, “Clinically studied probiotic.” The trials being alluded to belong to a strain the label does not identify. Because no strain is named, the count of human RCTs assignable to this product is zero — not because S. boulardii is unstudied, but because there is nothing here to attach the studies to.
What makes this more than a routine omission is the shelf next to it. Jarrow’s Jarro-Dophilus EPS, on the same website, names all eight of its strains. So does the 25-billion version. This is the one product in the line where the designator carries the entire clinical argument, and it is the one product with no designator. That is a choice.
Set against that, the rest of the label is good. The at-expiry guarantee is stated in the most consumer-facing language in its batch — “Minimum 5 billion viable cells at time of consumption”. The prebiotic is specified with a minimum-purity figure rather than a bare milligram number. Allergen disclosure is full. There is a candid note about capsule fill varying with particle size. And at $0.34 a day it is the cheapest product in its batch by roughly a factor of five.
One last thing worth recording plainly: Jarrow files this product under “Women’s Health” in its own on-page category list. S. boulardii has no sex-specific rationale, and none is given.